• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Once-a-Week Insulin Matches Daily Insulin in Lowering HbA1c: Daily Dose

News
Article
Once-a-Week Insulin Matches Daily Insulin in Lowering HbA1c: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


Last week, we reported on topline results of the international QWINT-2 and QWINT-4 studies announced by Eli Lilly.

The studies

QWINT-2 and QWINT-4 were parallel-design, open-label, treat-to-target randomized controlled trials comparing the safety and efficacy of Lilly's once-weekly efsitora to daily basal insulin degludec for 52 weeks and to basal insulin glargine for 26 weeks, respectively.

In the QWINT-2 study, 928 insulin-naïve adults with type 2 diabetes (T2D) were randomly assigned to receive either efsitora once weekly or insulin degludec once daily; the study design also allowed investigators to assess the investigational agent’s efficacy and safety among study participants using and not using GLP-1 receptor agonists.

The 26-week phase 3 QWINT-4 trial enrolled 730 adults with T2D previously treated with basal insulin glargine and at least 2 daily injections of mealtime insulin. Participants were randomly assigned to receive efsitora once weekly or insulin glargine once daily, both of which were administered with insulin lispro.

The findings

  • QWINT-2: At week 52, HbA1c reduction was 1.34% with efsitora compared to 1.26% for insulin degludec; final HbA1c levels were 6.87% and 6.95%, for the efficacy estimand, satisfying the study's primary endpoint.

  • QWINT-4: Efsitora was noninferior to traditional daily insulin glargine at week 26 for the primary endpoint of reduced HbA1c.

  • The safety and tolerability profile for efsitora in both trials was favorable.

Click here for more details.


Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.